This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Google Scholar
Right arrow Articles by Laue, H.
Right arrow Articles by Hawser, S.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Laue, H.
Right arrow Articles by Hawser, S.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 2009, p. 4542-4544, Vol. 53, No. 10
0066-4804/09/$08.00+0     doi:10.1128/AAC.00766-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

In Vitro Bactericidal Activity of Iclaprim in Human Plasma{triangledown}

Heike Laue,{dagger}* Tiziana Valensise,{ddagger} Aurélie Seguin,{ddagger} Sergio Lociuro, Khalid Islam, and Stephen Hawser§

Arpida AG, Reinach, Switzerland

Received 9 June 2009/ Returned for modification 10 July 2009/ Accepted 25 July 2009

This study evaluated the effect of human plasma on the in vitro bactericidal activity of the novel diaminopyrimidine iclaprim against methicillin (meticillin)-susceptible and -resistant Staphylococcus aureus strains. MICs and minimal bactericidal concentrations (MBCs) of iclaprim, with ~93% protein binding, were similar in the absence and in the presence of 50% human plasma; MICs and MBCs ranged from 0.06 to 0.125 µg/ml. Furthermore, the activity of iclaprim was not affected by plasma, with ≥99.9% reduction in CFU after 5.0 to 7.6 h.

* Corresponding author. Mailing address: Arpida AG, Duggingerstrasse 23, CH-4153 Reinach, Switzerland. Phone: 41 61 417 96 60. Fax: 41 61 417 96 61. E-mail: heike.laue{at}arpida.com

{triangledown} Published ahead of print on 3 August 2009.

{dagger} Present address: Givaudan Schweiz AG, Duebendorf, Switzerland.

{ddagger} Present address: Novartis, Basel, Switzerland.

§ Present address: IHMA Europe Sàrl, Epalinges, Switzerland.

Antimicrobial Agents and Chemotherapy, October 2009, p. 4542-4544, Vol. 53, No. 10
0066-4804/09/$08.00+0     doi:10.1128/AAC.00766-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»